

[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
 Patent and Exclusivity Search Results from query on Appl No 020622 Product 003 in the OB_Rx list.

Patent Data

Appl No	Prod No	Patent No	Patent Expiration	Drug Substance Claim	Drug Product Claim	Patent Use Code	Delist Requested
N020622	003	8232250	Aug 19, 2030			U - 441	
N020622	003	8399413	Aug 19, 2030			U - 441	

Exclusivity Data

Appl No	Prod No	Exclusivity Code	Exclusivity Expiration
N020622	003	NP	Jan 28, 2017

Additional information:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

[View a list of all patent use codes](#)

[View a list of all exclusivity codes](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research
 Office of Generic Drugs
 Division of Labeling and Program Support
 Update Frequency:
 Orange Book Data - **Monthly**
 Generic Drug Product Information & Patent Information - **Daily**
 Orange Book Data Updated Through December 2014
 Patent and Generic Drug Product Data Last Updated January 29, 2015

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>
2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](#)
6. [../default.cfm](#)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act](#) [Site Map](#) [Transparency](#) [Website Policies](#)

U.S. Food and Drug Administration
 10903 New Hampshire Avenue
 Silver Spring, MD 20993
 Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



For Government For Press

[Combination Products Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#) [Emergency Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry](#) [Health Professionals](#) [FDA Archive](#)

U.S. Department of **Health & Human Services**

Links on this page:



[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
 Search results from the "OB_Rx" table for query on "020622."

Active Ingredient:	GLATIRAMER ACETATE
Dosage Form;Route:	INJECTABLE;SUBCUTANEOUS
Proprietary Name:	COPAXONE
Applicant:	TEVA PHARMS USA
Strength:	20MG/ML
Application Number:	N020622
Product Number:	002
Approval Date:	Feb 12, 2002
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	

Patent and Exclusivity Info for this product: [View](#)

Active Ingredient:	GLATIRAMER ACETATE
Dosage Form;Route:	INJECTABLE;SUBCUTANEOUS
Proprietary Name:	COPAXONE
Applicant:	TEVA PHARMS USA
Strength:	40MG/ML
Application Number:	N020622
Product Number:	003
Approval Date:	Jan 28, 2014
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	

Patent and Exclusivity Info for this product: [View](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research
 Office of Generic Drugs
 Division of Labeling and Program Support
 Update Frequency:
 Orange Book Data - **Monthly**
 Generic Drug Product Information & Patent Information - **Daily**
 Orange Book Data Updated Through December 2014
 Patent and Generic Drug Product Data Last Updated January 29, 2015


Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>

2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](http://www.fda.gov/oc/default.cfm)
6. [../default.cfm](http://www.fda.gov/oc/default.cfm)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act Site Map](#) [Transparency Website Policies](#)



U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government](#) [For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#)
[Emergency Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing](#)
[Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry Health](#)
[Professionals](#) [FDA Archive](#)



U.S. Department of **Health & Human Services**

Links on this page:

[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Search results from the "OB_Rx" table for query on "020622."

Active Ingredient:	GLATIRAMER ACETATE
Dosage Form;Route:	INJECTABLE;SUBCUTANEOUS
Proprietary Name:	COPAXONE
Applicant:	TEVA PHARMS USA
Strength:	20MG/ML
Application Number:	N020622
Product Number:	002
Approval Date:	Feb 12, 2002
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	

Patent and Exclusivity Info for this product: [View](#)

Active Ingredient:	GLATIRAMER ACETATE
Dosage Form;Route:	INJECTABLE;SUBCUTANEOUS
Proprietary Name:	COPAXONE
Applicant:	TEVA PHARMS USA
Strength:	40MG/ML
Application Number:	N020622
Product Number:	003
Approval Date:	Jan 28, 2014
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	

Patent and Exclusivity Info for this product: [View](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:
Orange Book Data - **Monthly**
Generic Drug Product Information & Patent Information - **Daily**
Orange Book Data Updated Through December 2014
Patent and Generic Drug Product Data Last Updated January 29, 2015

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>

2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](http://www.fda.gov/oc/default.cfm)
6. [../default.cfm](http://www.fda.gov/oc/default.cfm)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).


[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act Site Map](#) [Transparency Website Policies](#)

U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government](#) [For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#)
[Emergency Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing Education](#)
[Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry Health Professionals](#) [FDA Archive](#)



Links on this page:

[FDA Home](#)³ [Drug Databases](#)⁴ [Orange Book](#)⁵

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Search results from the "OB_Rx" table for query on "020622."

Active Ingredient:	GLATIRAMER ACETATE
Dosage Form;Route:	INJECTABLE;SUBCUTANEOUS
Proprietary Name:	COPAXONE
Applicant:	TEVA PHARMS USA
Strength:	20MG/ML
Application Number:	N020622
Product Number:	002
Approval Date:	Feb 12, 2002
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	

Patent and Exclusivity Info for this product: [View](#)

Active Ingredient:	GLATIRAMER ACETATE
Dosage Form;Route:	INJECTABLE;SUBCUTANEOUS
Proprietary Name:	COPAXONE
Applicant:	TEVA PHARMS USA
Strength:	40MG/ML
Application Number:	N020622
Product Number:	003
Approval Date:	Jan 28, 2014
Reference Listed Drug	Yes
RX/OTC/DISCN:	RX
TE Code:	

Patent and Exclusivity Info for this product: [View](#)

[Return to Electronic Orange Book Home Page](#)⁶

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:

Orange Book Data - **Monthly**

Generic Drug Product Information & Patent Information - **Daily**

Orange Book Data Updated Through December 2014

Patent and Generic Drug Product Data Last Updated January 29, 2015

Links on this page:

1. <http://www.addthis.com/bookmark.php?u508=true&v=152&username=fdamain>

2. <http://www.addthis.com/bookmark.php>
3. <http://www.fda.gov/default.htm>
4. <http://www.fda.gov/Drugs/InformationOnDrugs/default.htm>
5. [../default.cfm](http://www.fda.gov/oc/default.cfm)
6. [../default.cfm](http://www.fda.gov/oc/default.cfm)

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

[Accessibility Contact](#) [FDA Careers](#) [FDA Basics](#) [FOIA No Fear Act Site Map](#) [Transparency Website Policies](#)



U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
[Email FDA](#)



[For Government](#) [For Press](#)

[Combination Products](#) [Advisory Committees](#) [Science & Research](#) [Regulatory Information](#) [Safety](#)
[Emergency Preparedness](#) [International Programs](#) [News & Events](#) [Training and Continuing](#)
[Education](#) [Inspections/Compliance](#) [State & Local Officials](#) [Consumers](#) [Industry Health](#)
[Professionals](#) [FDA Archive](#)



U.S. Department of **Health & Human Services**

Links on this page: